Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

PFIZER INC : Other Events (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 12:48pm CET

Item 8.01 Other Events On December 7, 2018, Pfizer Inc. ("Pfizer") issued a notice for the redemption in full of all €1,141,300,000 aggregate principal amount outstanding of its 5.750 per cent. Notes due 2021 (ISIN: XS0432071131; COMMON CODE: 043207113) (the "Notes").

The Notes will be redeemed on January 9, 2019 at a "make-whole" redemption price as set forth in the indenture, as supplemented, pursuant to which the Notes were issued. On the redemption date, the redemption price will become due and payable on the Notes and, unless Pfizer defaults in the payment of the redemption price, interest on the Notes will cease to accrue on and after the redemption date. The notice of redemption specifying the terms, conditions and procedures for the redemption is available through The Bank of New York Mellon, located at 240 Greenwich St., New York, New York 10286, as paying agent for the Notes. The foregoing does not constitute a notice of redemption for the Notes.

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
12/14PFIZER : Raises Dividend, Authorizes New Share Repurchase Plan
DJ
12/14PFIZER : Declares First-Quarter 2019 Dividend
BU
12/14PFIZER : Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ ..
BU
12/14Merck bolsters animal health unit with $2.4 billion Antelliq purchase
RE
12/14PFIZER : Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine ..
BU
12/13MARKETS RIGHT NOW : Stocks open higher on Wall Street
AQ
12/12Eli Lilly, AC Immune Ink Alzheimer's Collaboration -- Update
DJ
12/11MARKET SNAPSHOT: U.S. Stocks Close Mostly Lower In Volatile Trade
DJ
12/11PFIZER : Thinking about buying stock in Caterpillar Inc., DSW Inc., Innovate Bio..
PR
12/11PFIZER INC. : Shares Bought by OLD Mutual Customised Solutions Proprietary Ltd.
AQ
More news
Financials ($)
Sales 2018 53 590 M
EBIT 2018 20 023 M
Net income 2018 13 007 M
Debt 2018 28 504 M
Yield 2018 3,13%
P/E ratio 2018 19,08
P/E ratio 2019 18,13
EV / Sales 2018 5,27x
EV / Sales 2019 5,19x
Capitalization 254 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 44,8 $
Spread / Average Target 2,2%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER20.93%254 040
JOHNSON & JOHNSON-4.81%356 703
NOVARTIS5.61%223 295
ROCHE HOLDING LTD.1.38%216 307
MERCK AND COMPANY35.92%198 877
AMGEN10.45%122 391